Croatia, Pharma and Corruption - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croatia, Pharma and Corruption
Croatia is on track to join the EU in 2013 and offers a well-developed pharmaceutical market. However, its EU membership application has undergone much scrutiny because of concerns regarding corruption, organised crime and counterfeit pharmaceuticals.


Pharmaceutical Technology Europe
Volume 23, Issue 8

References

1. BBC News, "Croatia cleared for EU membership in 2013" (UK, 2011). http://www.bbc.co.uk/, accessed 30 June 2011.

2. Business Monitor, Croatia Pharmaceuticals and Healthcare Report Q3 (UK, May 2011).

3. ANZAG, "ANZAG: Result under pressure" press release (Germany, 2011) http://www.anzag.de/, accessed 30 June 2011.

4. Epsicom, The Outlook for Pharmaceuticals in Central & Eastern Europe (UK, April 2011).

5. L. Voncina and T. Strizrep, Eurohealth 16 (4), 20–22 (2011).

6. L. Voncina "Croatian 2009–2010 pharma reform", Ekonom:east Media Group, online (Serbia, 2011), http://www.emg.rs/, accessed 30 June 2011.

7. FarmaVita.Net, "Croatia — Pharmaceuticals and Biotechnology" (2011), http://www.farmavita.net/, accessed 29 June 2011.

8. Pliva, "Pliva: History" (Croatia), http://www.pliva.com/, accessed 30 June 2011.

9. The Guardian, "US embassy cables: Allegations over Croatian pharmaceutical company deal rebutted" (UK, 2010) http://www.guardian.co.uk/, accessed 30 June 2011.

10. PETO EVIC, "Croatia Fights Counterfeiting" (Belgium, 2011). http://www.petosevic.com/, accessed 30 June 2011.

11. Securing Pharma, "Croatian study uncovers counterfeit medicines" (2010) http://www.securingpharma.com/, accessed 29 June 2011.

12. V. Stecher et al., 12th Congress of the European Society for Sexual Medicine (Lyon, France, 2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here